Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:TPTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTPTXTurning Point TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTPTXTurning Point TherapeuticsN/A16.8316.83OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipTPTXTurning Point Therapeutics8.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableTPTX HeadlinesSourceHeadlineGlass System in Turning Point Residencearchdaily.com - April 2 at 10:51 AMBid to remove prosecutors sets up turning point in Trump’s Georgia casepolitico.com - February 19 at 11:51 PMTurning Point Brands Inc.wsj.com - February 17 at 11:42 PMAlzheimer’s: A Turning Point?bbc.co.uk - February 12 at 4:29 PMTurning Point Brands Inc (TPB)investing.com - February 10 at 7:36 PMCormorant Asset Management, LP's Net Worthbenzinga.com - February 10 at 7:36 PMSolving quadratic equations - Edexcelbbc.co.uk - January 15 at 9:15 AMCOP15: A Turning Point for Investor Approaches to Biodiversitymorningstar.com - December 19 at 12:52 PMTurning Point USA: Are conservatives fighting back on campus?bbc.com - December 16 at 3:14 PMBMS bet looking good as Augtyro approved in ROS1-positive NSCLCthepharmaletter.com - November 16 at 12:30 PMPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodulster.ac.uk - October 29 at 7:58 PMA Turning Point for Japan-US Climate Cooperation?thediplomat.com - October 28 at 1:00 PMWhat to know about the Turning Point USA incident on Arizona State University's campusazcentral.com - October 28 at 1:00 PMRight-wingers start to turn on this pro-Trump propaganda groupmsnbc.com - October 28 at 1:00 PMUAW, Detroit Three careen toward another Friday turning pointautoblog.com - October 16 at 6:04 PMTrump's youth whisperers living large as MAGA candidates failmsnbc.com - October 14 at 1:16 PMSong Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...Song Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...koimoi.com - October 5 at 8:10 AMThe revised economic figures are a huge lucky break for Sunak – and could be a turning pointindependent.co.uk - September 17 at 4:14 PMDespite previous campus firestorm, Turning Point USA to welcome conservative speakers at ASUazcentral.com - September 15 at 12:34 AMThis law may be the turning point in America’s fight to save the planetmsnbc.com - August 21 at 7:44 AMTattoos have reached a turning point at workft.com - July 29 at 11:36 PMTurning Point’s #ACTCON was a pro-Trump lovefest designed to intimidatemsnbc.com - July 25 at 10:25 AM‘Turning point’ in the fight against Alzheimer’s as drug found to slow diseaseindependent.co.uk - July 23 at 3:37 PMMargaret Thatcher, a turning point in British politicsen.mercopress.com - July 19 at 12:55 PMNew MarketBeat Followers Over TimeCompany DescriptionsTurning Point TherapeuticsNASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
